SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : SANGUINE CORP. (SGNC) -- Ignore unavailable to you. Want to Upgrade?


To: Jim DH who wrote (3682)8/12/1998 9:25:00 AM
From: dwlima  Read Replies (1) | Respond to of 5402
 
Northfield Laboratories (a development stage company) is engaged in the development of an alternative to transfused blood for use in the treatment of acute blood loss. For the nine months ended 2/28/98, the Company reported no revenues. Net loss increased 31% to $4.2 million. Results reflect increased R&D expenses related to the Phase III clinical trials. Results also reflect increased S/G/A costs due to higher travel and professional services expenses.

Big losses, no revenues and a market cap of $250 million. well, if we were in phase 3 with a product and had the same market cap, we would have a stock price of $12.50. upside is huge and downside seems to be limited at this point as i think there is always a 30-cent (or few million dollar value) until we see test results.

just my opinion
dwlima



To: Jim DH who wrote (3682)8/12/1998 2:54:00 PM
From: drdan  Respond to of 5402
 
Hi, everyone....back from the world of big-board stocks....the FDA's reasons for expanding the trial patient group is strange....nobody knows how many patients are enough patients to test for Joe Six-Pack to feel safe about having this transfused into himself.....maybe the FDA is telling Northfield it needs to use more patients so that their data will be statistically significant(so that any results would not be due to chance). In any case, a delay for Northfield doesn't hurt our cause!